The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Cubist Pharmaceuticals Inc.  (CBST) Trade Now »     Rate CBST  -  Discuss CBST  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate CBST:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

CBST: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX Graphic_rating_buy CBST
Mikerun
73%
 -0.76%
in 124 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 243 entries as of 7/7/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
By  Mike Havrilla   (+1.04%  risk: conservative)  07/07/09 Comment


EU approves Cubicin Graphic_rating_buy CBST
20105205_1_
75%
 -31.21%
in 358 days

EU approves Novartis' Cubicin to treat hospital infections

FDLI SmartBrief | 11/07/2008

The European Union has approved Cubicin for expanded use in patients suffering from potentially fatal infections commonly contracted during hospital stays. The two new indications approved were right-sided infective endocarditis due to Staphylococcus aureus, an infection of the heart valve, and Staphylococcus aureus bacteremia, a bloodstream infection. Reuters (09/05)

By  ariesdragon   (+16.88%  risk: conservative)  11/14/08 Comment


Bullish on CBST ... Graphic_rating_buy CBST
Foto
62%
 -12.11%
in 483 days
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $29 Analysts' Targets Stanford Group Company $34 Buy Wednesday, July 02, 2008 Needham & Co. $24 Buy Tuesday, July 01, 2008 Robert W. Baird & Co. $28 Outperform Tuesday, January 15, 2008 Cubist Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products that address medical needs in the acute care environment in the Untied States, the European Union, Argentina, Canada, India, Israel, Korea...
By  Marian Filo   (-24.55%  risk: aggressive)  07/12/08 Comment




From the Blogosphere

What We Like About Cubist Pharma

We are carefully entering portfolio positions in this environment. (Note: Portfolio positions vs. trading positions) A company that we like for its specialty product is Cubist Pharmaceuticals (CBST). It has made all of our screens recently, but we were reluctant to add it to portfolios as the very recent trends have been down, down, down. The official line from the company’s description page:

<>

<>Cubist Pharmaceuticals, Inc. (Cubist), is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the ...
By  trackseekingalpha   (-14.41%  risk: aggressive)  11/05/09 Comment


Cubist Pharma (CBST) – What we like about it…
We are carefully entering portfolio positions in this environment. (Note: Portfolio positions vs. trading positions) A company that we like for its specialty product is Cubist Pharmaceuticals (CBST). It has made all of our screens recently, but we were reluctant to add it to portfolios as the very recent trends have been down, down, down.  [...] Related posts:
  1. Apple (AAPL) Earnings – Quick Notes
  2. Allegiant (ALGT) – October YoY Comps Are Strong
  3. Video: NYT Walt Mossberg Raves about Microsoft (MSFT) Windows 7
By  Andrew Horowitz   (-11.35%  risk: moderate)  11/05/09 Comment


DSW, Polaris, Fairchild Semiconductor, Cypress Semiconductor All Guide Higher
Stop
56%
TempurPedic Raises Guidance
TempurPedic International Inc. (TPX) said it expects 2009 earnings of $1.00 to $1.05 per share on revenue of $790.0 million to $805.0 million. The company's previous guidance was earnings of $0.70 to $0.90 per share on revenue of $700.0 million to $740.0 million and the current consensus earnings estimate is $0.87 per share on revenue of $736.6 million for the year ending December 31, 2009.


SuccessFactors Guides Higher
SuccessFactors (SFSF) said it expects third quarter revenue of $38.2 million to $38.7 million. The company's previous guidance was revenue of $37.2 m...
By  s J   (-18.05%  risk: aggressive)  10/16/09 Comment


Options activity in biotech bets
16%

"Two biotechs in our portfolio have seen an unusual amount of option activity in recent weeks/months," notes 20-year sector veteran Nate Pile. Here's the latest in Nate's Notes.

"The first one is Cubist Pharmaceuticals (NASDAQ: CBST), and the option trading here appears to be pretty much a bullish bet no matter how you slice it.

"Further, Cubist’s stock has continued to climb in a manner consistent with what one would expect to see in the early stages of a bull market. Of course, I only consider these technical issues after being bullish based on the company's fundamentals.)

<>"On the oth...
By  The Stock Advisors   (-19.48%  risk: moderate)  09/21/09 Comment


Analyst upgrades, downgrades and initiations: VZ, T, GT, RIO, XRX, MA ...

Filed under: Analyst reports, Analyst upgrades and downgrades, AT and T (T), MasterCard Inc'A' (MA), Xerox Corp (XRX), Verizon Communications (VZ), Analyst initiations, Goodyear Tire and Rubber (GT)

Analyst upgrades:
<>
  • Citigroup upgraded WebMD (NASDAQ: WBMD) shares to Buy from Hold on valuation following the company's Q4 results and outlook. The firm maintains a $25 target on the stock.
  • Goldman upgraded Verizon (NYSE: VZ) and AT&T (NYSE: T) to Buy from Neutral based on valuation and expectations for 2010 earnings growth.
    • <>Roth upgraded Maxwell Tech (NASDAQ: MXWL) to Buy from Hold fol...
    By  Eric Buscemi   (+0.00%)  02/20/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +35.25% 368
    2 Gerald Greene 18.14 +70.90% 206
    3 stockmarketfunding.com 17.66 +25.78% 53
    4 akiralegrand 13.47 +14.32% 60
    5 anup2104 12.13 +69.23% 34


    POPULAR STOCKS
    Symbol Company Name Sentiment
    SBUX Starbucks Corp
    ETFC E*Trade Financial Corp
    BAC Bank of America Corp
    FSLR First Solar Inc.
    FNM Fannie Mae
    WM Washington Mutual Inc

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on CBST

    Visit streetinsider.com


    Discussion Wall + Add  

    Be the first to start a discussion and earn 2 points.



    More Resources

    Graphic_arrow1 About Cubist Pharmaceuticals Inc. - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch